20 results on '"Di Sarno, R."'
Search Results
2. T06.01.9 THE BISPHENOL A INDUCED WORSENING OF NON-ALCOHOLIC FATTY LIVER DISEASE: A CLINICAL STRATEGY TO ANTAGONIZE THE PROGRESSION OF THE DISEASE
- Author
-
Dallio, M., Gravina, A.G., Masarone, M., Diano, N., Nicolucci, C., Errico, S., Di Sarno, R., Tuccillo, C., Stiuso, P., Morisco, F., Persico, M., Loguercio, C., and Federico, A.
- Published
- 2020
- Full Text
- View/download PDF
3. P.09.18 DIETARY INTAKE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: QUALITATIVE AND QUANTITATIVE EVALUATION
- Author
-
Caprio, G.G., Dallio, M., Gravina, A.G., Di Sarno, R., Loguercio, C., and Federico, A.
- Published
- 2018
- Full Text
- View/download PDF
4. OC.16.2 EVALUATION OF UROTENSIN II RECEPTOR EXPRESSION IN PATIENTS WITH ULCERATIVE COLITIS
- Author
-
Gravina, A.G., Dallio, M., Caprio, G.G., Picascia, D., Di Sarno, R., Tuccillo, C., Martorano, M., Loguercio, C., and Federico, A.
- Published
- 2018
- Full Text
- View/download PDF
5. P.09.8: Role of Bisphenol a as Environmental Factor in the Promotion of Non-Alcoholic Fatty Liver Disease: In VITRO and in VIVO Protective Effects of Silybin
- Author
-
Federico, A., Dallio, M., Errico, S., Caprio, G.G., Nicolucci, C., Di Sarno, R., Gionti, L., Tuccillo, C., Diano, N., and Loguercio, C.
- Published
- 2017
- Full Text
- View/download PDF
6. P.08.8: Silybin in Combination with Regorafenib as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer Patients
- Author
-
Dallio, M., Troiani, T., Di Sarno, R., Belli, V., Napolitano, S., Gravina, A.G., Sgambato, D., Romano, M., Ciardiello, F., Loguercio, C., and Federico, A.
- Published
- 2017
- Full Text
- View/download PDF
7. Chemical effect of bisphenol a on non-alcoholic fatty liver disease
- Author
-
Sonia Errico, Mario Masarone, Luigi Boccuto, Carla Nicolucci, Emidio Scarpellini, Ludovico Abenavoli, Alessandro Federico, Vittorio Patanè, Antonietta Gerarda Gravina, Marcello Dallio, Marcello Persico, Nadia Diano, Mario Romeo, Carmelina Loguercio, Rosa Di Sarno, Dallio, M., Diano, N., Masarone, M., Gravina, A. G., Patane, V., Romeo, M., Di Sarno, R., Errico, S., Nicolucci, C., Abenavoli, L., Scarpellini, E., Boccuto, L., Persico, M., Loguercio, C., and Federico, A.
- Subjects
Hepatocellular carcinoma ,Health, Toxicology and Mutagenesis ,bisphenol A ,lcsh:Medicine ,Review ,Disease ,Endocrine Disruptors ,Bioinformatics ,Chronic liver disease ,ACTIVATION ,0302 clinical medicine ,Bisphenol A ,oxidative stress ,Public, Environmental & Occupational Health ,GENE-EXPRESSION ,0303 health sciences ,INSULIN-RESISTANCE ,Fatty liver ,hepatocellular carcinoma ,BPA ,030220 oncology & carcinogenesis ,HEALTH ,LIPID-ACCUMULATION ,Life Sciences & Biomedicine ,PERINATAL EXPOSURE ,endocrine-disrupting compounds ,Environmental Sciences & Ecology ,METABOLISM ,03 medical and health sciences ,Metabolic Diseases ,Phenols ,medicine ,Animals ,Humans ,Endocrine system ,Benzhydryl Compounds ,030304 developmental biology ,Science & Technology ,business.industry ,lcsh:R ,Public Health, Environmental and Occupational Health ,nutritional and metabolic diseases ,Type 2 Diabetes Mellitus ,non-alcoholic fatty liver disease ,Environmental Exposure ,medicine.disease ,Obesity ,Endocrine-disrupting compounds ,Non-alcoholic fatty liver disease ,Oxidative stress ,Endocrine-disrupting compound ,Metabolic syndrome ,business ,Environmental Sciences ,Hormone - Abstract
Non-alcoholic fatty liver disease (NAFLD) is considered a predominant chronic liver disease worldwide and a component of metabolic syndrome. Due to its relationship with multiple organs, it is extremely complex to precisely define its pathogenesis as well as to set appropriate therapeutic and preventive strategies. Endocrine disruptors (EDCs) in general, and bisphenol A (BPA) in particular, are a heterogeneous group of substances, largely distributed in daily use items, able to interfere with the normal signaling of several hormones that seem to be related to type 2 diabetes mellitus (T2DM), obesity, and other metabolic disorders. It is reasonable to hypothesize a BPA involvement in the pathogenesis and evolution of NAFLD. However, its mechanisms of action as well as its burden in the vicious circle that connects obesity, T2DM, metabolic syndrome, and NAFLD still remain to be completely defined. In this review we analyzed the scientific evidence on this promising research area, in order to provide an overview of the harmful effects linked to the exposure to EDCs as well as to frame the role that BPA would have in all phases of NAFLD evolution. ispartof: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH vol:16 issue:17 ispartof: location:Switzerland status: published
- Published
- 2019
8. Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: In vitro and clinical study
- Author
-
Mario Masarone, L. Gionti, Alessandro Federico, Carmela Loguercio, Carla Nicolucci, Paola Stiuso, Antonietta Gerarda Gravina, Marcello Dallio, R. Di Sarno, Sonia Errico, Concetta Tuccillo, Marcello Persico, Nadia Diano, Dallio, M., Masarone, M., Errico, S., Gravina, A. G., Nicolucci, C., Di Sarno, R., Gionti, L., Tuccillo, C., Persico, M., Stiuso, P., Diano, N., Loguercio, C., and Federico, A.
- Subjects
0301 basic medicine ,Adult ,Male ,endocrine system ,medicine.medical_specialty ,Bisphenol ,Thiobarbituric acid ,Urine ,010501 environmental sciences ,01 natural sciences ,03 medical and health sciences ,chemistry.chemical_compound ,Phenols ,Non-alcoholic Fatty Liver Disease ,Diabetes mellitus ,Internal medicine ,medicine ,TBARS ,Humans ,Pharmacology (medical) ,Benzhydryl Compounds ,0105 earth and related environmental sciences ,Aged ,Cell Proliferation ,Hepatology ,business.industry ,Fatty liver ,Fatty Acids ,Gastroenterology ,Case-control study ,Hep G2 Cells ,Middle Aged ,medicine.disease ,030104 developmental biology ,Endocrinology ,chemistry ,Diabetes Mellitus, Type 2 ,Case-Control Studies ,Environmental Pollutants ,Female ,Steatohepatitis ,business - Abstract
Background: Bisphenol A is an endocrine disrupting chemical associated with type 2 diabetes mellitus (T2DM), cardiovascular disease and liver enzyme abnormalities. Aim: To evaluate bisphenol A plasma and urine levels in non-alcoholic fatty liver disease (NAFLD) patients compared to healthy subjects. Furthermore, we evaluated, in human HepG2 cells, the effects of exposure to different concentrations of bisphenol A on both oxidative stress induction and cell proliferation. Methods: We enrolled 60 patients with histological diagnosis of NAFLD with or without T2DM and sixty healthy subjects. In vitro, the proliferation of bisphenol A-exposed HepG2 cells at two different concentrations (0.025 and 0.05 μM) was evaluated, both at high (H-HepG2) and at low (L-HepG2) glucose concentrations for 48 h. Lipoperoxidation was assessed by thiobarbituric acid reactive substances (TBARS) assay. Results: Bisphenol A levels were significantly higher in 60 NAFLD subjects, both in urine and in plasma (P < 0.0001) when compared to controls and, in this group, it appeared to be higher in 30 non-alcoholic steatohepatitis patients compared to 30 simple steatosis subjects (P < 0.05), independently from the presence of T2DM. After a bisphenol A-free diet for 1 month, NAFLD patients showed a significant reduction in bisphenol A circulating levels (P < 0.05), without a significant reduction in urine levels. H-HepG2 cells treated with bisphenol A (0.05 μM) increased proliferation compared to controls at 48 h (P < 0.0001). Bisphenol A increased TBARS levels at 48 h versus controls. Conclusions: Our study reveals a possible role of bisphenol A as an environmental factor involved in the promotion of NAFLD, particularly in T2DM patients.
- Published
- 2018
9. Monkeypox Clinical Features and Differential Diagnosis: First Case in Campania Region.
- Author
-
Carannante N, Tiberio C, Bellopede R, Liguori M, Di Martino F, Maturo N, Di Sarno R, Scarica S, Fusco G, Cardillo L, de Martinis C, Atripaldi L, and Perrella A
- Abstract
As of 15 June, there have been, globally, a total of 2103 laboratory-confirmed cases and one probable case of Monkeypox, including one death. We report two cases of vesicular infectious diseases, one of those is the first case of Monkeypox in the Campania Region. The report, therefore, highlights a recrudescent infection disease that could represent a challenge in differential diagnosis with other vesicular infectious diseases such as Varicella Zoster Virus, during a pandemic season that does not seem to end. Indeed, varicella should be carefullu considered in differential diagnosis according to its vesicular or pustular rash to have a prompt diagnosis and public health response in case of monkeypox infection.
- Published
- 2022
- Full Text
- View/download PDF
10. Critical review on the use and abuse of alcohol. When the dose makes the difference.
- Author
-
Di Sarno R, Brigida A, Caprio GG, Ciardiello D, Dallio M, Sangineto M, Fagoonee S, Abenavoli L, Luzza F, Gravina AG, De Magistris L, Federico A, and Loguercio C
- Subjects
- Alcoholism complications, Alcoholism genetics, Animals, Disease Models, Animal, Ethanol administration & dosage, Humans, Neoplasms etiology, Polymorphism, Genetic, Alcohol Drinking adverse effects, Alcohol Drinking genetics, Alcoholism diagnosis
- Abstract
Nowadays harmful alcohol consumption represents one of the most important risk factors for the development of several type of chronic and acute diseases in the western countries, contributing to a great number of deaths. Focusing the attention on cancer development and progression, the scientific community has a large consensus in declaring the existence of a harmful association between alcohol consumption and liver, breast, upper aerodigestive tract (mouth, oropharynx, hypopharynx, and esophagus), pancreas and colon cancer appearance. However the precise biological links by which the alcohol could be responsible for cancer initiation and progression are not fully understood yet, even if the International Agency for Research on Cancer (IARC) indicated both ethanol and acetaldehyde as carcinogen for humans. The possible explanation of the effect exerted by ethanol and acetaldehyde could be related to direct genotoxicity, hormonal disturbance, triggering of oxidative stress and inflammation. In this review, we examine the relationship between alcohol dosage and associated diseases, with focus on alcohol-related cancers. Furthermore, to understand the potential molecular mechanisms of these diseases, the results of in vivo experiments on animal models were discussed.
- Published
- 2020
- Full Text
- View/download PDF
11. Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is Associated With Fast Clinical and Radiological Healing: Case Report.
- Author
-
Carannante N, Fiorentino G, Corcione A, Di Sarno R, Spatarella M, Maturo N, Fragranza F, and Di Micco P
- Abstract
Polyclonal preparation of IgM as an adjuvant therapy has been reported as a relevant immunomodulant therapy in several infectious diseases, exhibiting, in most cases, improvement of the clinical course. No drug has demonstrated therapeutic efficacy for COVID-19. Immunomodulatory treatment with hydroxychloroquine and biologics as tocilizumab, in fact, has not proven to show satisfactory results in several reports. We therefore treated a selected patient with interstitial multifocal pneumonia, positive to COVID-19, with polyclonal preparation of immunoglobulins as an adjuvant therapy, obtaining in few days clinical remission and improvements in radiological findings. Based on this case report, we suggest that clinical trials are conducted to test the efficacy and safety of polyclonal immunoglobulins for adjunctive therapy of COVID-19., (Copyright © 2020 Carannante, Fiorentino, Corcione, Di Sarno, Spatarella, Maturo, Fragranza and Di Micco.)
- Published
- 2020
- Full Text
- View/download PDF
12. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients.
- Author
-
Federico A, Dallio M, Masarone M, Gravina AG, Di Sarno R, Tuccillo C, Cossiga V, Lama S, Stiuso P, Morisco F, Persico M, and Loguercio C
- Subjects
- Adult, Aged, Biomarkers blood, Body Weight, Cytokines blood, Drug Therapy, Combination, Female, Humans, Insulin Resistance, Liver metabolism, Male, Middle Aged, Oxidative Stress, Endothelial Cells physiology, Liver pathology, Non-alcoholic Fatty Liver Disease diet therapy, Silybin therapeutic use, Vitamin D therapeutic use, Vitamin E therapeutic use
- Abstract
Nowadays, the nonalcoholic fatty liver disease represents the main chronic liver disease in the Western countries, and the correct medical therapy remains a big question for the scientific community. The aim of our study was to evaluate the effect derived from the administration for six months of silybin with vitamin D and vitamin E (RealSIL 100D®) on metabolic markers, oxidative stress, endothelial dysfunction, and worsening of disease markers in nonalcoholic fatty liver disease patients. We enrolled 90 consecutive patients with histological diagnosis of nonalcoholic fatty liver disease and 60 patients with diagnosis of reflux disease (not in therapy) as healthy controls. The nonalcoholic fatty liver disease patients were randomized into two groups: treated (60 patients) and not treated (30 patients). We performed a nutritional assessment and evaluated clinical parameters, routine home tests, the homeostatic model assessment of insulin resistance, NAFLD fibrosis score and fibrosis-4, transient elastography and controlled attenuation parameter, thiobarbituric acid reactive substances, tumor necrosis factor α , transforming growth factor β , interleukin-18 and interleukin-22, matrix metalloproteinase 2, epidermal growth factor receptor, insulin growth factor-II, cluster of differentiation-44, high mobility group box-1, and Endocan. Compared to the healthy controls, the nonalcoholic fatty liver disease patients had statistically significant differences for almost all parameters evaluated at baseline ( p < 0.05). Six months after the baseline, the proportion of nonalcoholic fatty liver disease patients treated that underwent a statistically significant improvement in metabolic markers, oxidative stress, endothelial dysfunction, and worsening of disease was greater than not treated nonalcoholic fatty liver disease patients ( p < 0.05). Even more relevant results were obtained for the same parameters by analyzing patients with a concomitant diagnosis of metabolic syndrome ( p < 0.001). The benefit that derives from the use of RealSIL 100D could derive from the action on more systems able to advance the pathology above all in that subset of patients suffering from concomitant metabolic syndrome., Competing Interests: The authors declare no conflict of interest., (Copyright © 2019 Alessandro Federico et al.)
- Published
- 2019
- Full Text
- View/download PDF
13. Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease.
- Author
-
Dallio M, Diano N, Masarone M, Gravina AG, Patanè V, Romeo M, Di Sarno R, Errico S, Nicolucci C, Abenavoli L, Scarpellini E, Boccuto L, Persico M, Loguercio C, and Federico A
- Subjects
- Animals, Environmental Exposure adverse effects, Humans, Metabolic Diseases etiology, Benzhydryl Compounds toxicity, Endocrine Disruptors toxicity, Non-alcoholic Fatty Liver Disease etiology, Phenols toxicity
- Abstract
Non-alcoholic fatty liver disease (NAFLD) is considered a predominant chronic liver disease worldwide and a component of metabolic syndrome. Due to its relationship with multiple organs, it is extremely complex to precisely define its pathogenesis as well as to set appropriate therapeutic and preventive strategies. Endocrine disruptors (EDCs) in general, and bisphenol A (BPA) in particular, are a heterogeneous group of substances, largely distributed in daily use items, able to interfere with the normal signaling of several hormones that seem to be related to type 2 diabetes mellitus (T2DM), obesity, and other metabolic disorders. It is reasonable to hypothesize a BPA involvement in the pathogenesis and evolution of NAFLD. However, its mechanisms of action as well as its burden in the vicious circle that connects obesity, T2DM, metabolic syndrome, and NAFLD still remain to be completely defined. In this review we analyzed the scientific evidence on this promising research area, in order to provide an overview of the harmful effects linked to the exposure to EDCs as well as to frame the role that BPA would have in all phases of NAFLD evolution.
- Published
- 2019
- Full Text
- View/download PDF
14. Effects of progestogens in women with preterm premature rupture of membranes.
- Author
-
Di Sarno R, Raffone A, and Saccone G
- Subjects
- 17 alpha-Hydroxyprogesterone Caproate administration & dosage, Female, Gestational Age, Humans, Infant, Newborn, Pregnancy, Pregnancy Outcome, Progesterone administration & dosage, Randomized Controlled Trials as Topic, Fetal Membranes, Premature Rupture drug therapy, Premature Birth prevention & control, Progestins administration & dosage
- Abstract
Different strategies have been adopted for prevention of spontaneous preterm birth, including use of progestogens. So far, five randomized trials have been published evaluating the efficacy of progestogens in women with PPROM, including a total of 425 participants. All the five trials enrolled pregnant women with singleton pregnancies randomized between 20 and 34 weeks of gestation. In four trials women were randomized to either weekly intramuscular 250 mg 17α-hydroxyprogesterone-caproate or placebo, while Mirzaei et al. was a three arms trials in which women received weekly intramuscular 250 mg 17α-hydroxyprogesterone-caproate, or rectal progesterone 400 mg daily, or no treatment. In all the trials, latency antibiotics were used, and tocolysis was used permitted for first 48 hours at discretion of attending physician. Recently a meta-analysis including the five trials has been published. They found that when compared to placebo weekly intramuscular 250 mg 17α-hydroxyprogesterone-caproate did not alter the latency period to delivery in singleton gestations with PPROM. Additionally, there was no difference in gestational age at delivery between groups or in mode of delivery. No significant differences were reported in maternal or neonatal outcomes, with latency not significantly altered in sensitivity analyses. So far, no trials have been published evaluating natural vaginal progesterone in women with PPROM.
- Published
- 2019
- Full Text
- View/download PDF
15. Neonatal pertussis diagnosis: low procalcitonin level and high lymphocyte count are able to discriminate pertussis from bacterial and viral infections.
- Author
-
Tascini C, Carannante N, Sodano G, Tiberio C, Atripaldi L, Di Caprio G, Sozio E, Sbrana F, Ripoli A, Menchini C, Galli L, Di Sarno R, Chiappini E, Sarno M, and Siani P
- Subjects
- Biomarkers blood, Humans, Infant, Infant, Newborn, Virus Diseases blood, Virus Diseases diagnosis, Bacterial Infections blood, Bacterial Infections diagnosis, Lymphocyte Count, Procalcitonin blood, Whooping Cough diagnosis
- Abstract
Pertussis is quite frequent and severe among infants; therefore, rapid diagnosis and timely targeted therapy are essential. Although a molecular test for etiological diagnosis is now available, it may not be available everywhere, and therefore adjunctive diagnostic tests are still useful for presumptive diagnosis. We describe the use of procalcitonin (PCT) and lymphocyte count to discriminate among pertussis, bacterial and viral infections. Fourteen infants per group were studied. The decision tree, built considering all available variables, showed a major role of PCT in predicting the different groups. A PCT value equal to or greater than 0.75 ng/ml selected for bacterial infections. A PCT value lower than 0.75 ng/ml and a lymphocyte count equal to or greater than 10,400/mm3 selected the subjects with pertussis, while a lymphocyte count lower than 10,400/mm3 selected for viral etiology. PCT should be used in the diagnosis of infants suspected of having pertussis.
- Published
- 2019
16. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
- Author
-
Quist-Nelson J, Parker P, Mokhtari N, Di Sarno R, Saccone G, and Berghella V
- Subjects
- 17 alpha-Hydroxyprogesterone Caproate administration & dosage, Female, Fetal Membranes, Premature Rupture physiopathology, Humans, Pregnancy, Progestins administration & dosage, Randomized Controlled Trials as Topic, Time Factors, 17 alpha-Hydroxyprogesterone Caproate therapeutic use, Fetal Membranes, Premature Rupture drug therapy, Premature Birth prevention & control, Progestins therapeutic use
- Abstract
Objective Data: Preterm prelabor rupture of membranes occurs in 3% of all pregnancies. Neonatal benefit is seen in uninfected women who do not deliver immediately after preterm prelabor rupture of membranes. The purpose of this study was to evaluate whether the administration of progestogens in singleton pregnancies prolongs pregnancy after preterm prelabor rupture of membranes., Study: Searches were performed in MEDLINE, OVID, Scopus, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials with the use of a combination of keywords and text words related to "progesterone," "progestogen," "prematurity," and "preterm premature rupture of membranes" from the inception of the databases until January 2018. We included all randomized controlled trials of singleton gestations after preterm prelabor rupture of membranes that were randomized to either progestogens or control (either placebo or no treatment). Exclusion criteria were trials that included women who had contraindications to expectant management after preterm prelabor rupture of membranes (ie, chorioamnionitis, severe preeclampsia, and nonreassuring fetal status) and trials on multiple gestations. We planned to include all progestogens, including but not limited to 17-α hydroxyprogesterone caproate, and natural progesterone., Study Appraisal and Synthesis Methods: The primary outcome was latency from randomization to delivery. Metaanalysis was performed with the use of the random effects model of DerSimonian and Laird to produce relative risk with 95% confidence interval. Analysis was performed for each mode of progestogen administration separately., Results: Six randomized controlled trials (n=545 participants) were included. Four of the included trials assessed the efficacy of 17-α hydroxyprogesterone caproate; 1 trial assessed rectal progestogen, and 1 trial had 3 arms that compared 17-α hydroxyprogesterone caproate, rectal progestogen, and placebo. The mean gestational age at time randomization was 26.9 weeks in the 17-α hydroxyprogesterone caproate group and 27.3 weeks in the control group. 17-α Hydroxyprogesterone caproate administration was not found to prolong the latency period between randomization and delivery (mean difference, 0.11 days; 95% confidence interval, -3.30 to 3.53). There were no differences in mean gestational age at delivery, mode of delivery, or maternal or neonatal outcomes between the 2 groups. Similarly, there was no difference in latency for those women who received rectal progesterone (mean difference, 4.00 days; 95% confidence interval, -0.72 to 8.72)., Conclusion: Progestogen administration does not prolong pregnancy in singleton gestations with preterm prelabor rupture of membranes., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
17. Gut microbiota, obesity and metabolic disorders.
- Author
-
Federico A, Dallio M, DI Sarno R, Giorgio V, and Miele L
- Subjects
- Adipose Tissue metabolism, Body Mass Index, Diabetes Mellitus, Type 2 microbiology, Humans, Metabolic Diseases metabolism, Metabolic Syndrome microbiology, Non-alcoholic Fatty Liver Disease microbiology, Obesity microbiology, Adipose Tissue microbiology, Diet, Gastrointestinal Microbiome, Metabolic Diseases microbiology
- Abstract
Obesity, diabetes and metabolic disorders represent hugely significant problems concerning the health in Western countries and the study of gut microbiota in metabolic pathologies is part of this framework. Diet effects on intestinal microbial composition and its role in pathogenetic mechanisms responsible for both obesity and systemic, hepatic and adipose tissue inflammation, represent at the moment one of this mostpromising topic in gastroenterology research. Gut health safety is essential, but it needs to be further explored in order to understand and interrupt the pathogenetic mechanisms, which support a large number of diseases. The aim of this review is to describe what are the modifications of gut microbial composition that occur in metabolic disorders and the role of gut microbiota in the pathogenesis of several diseases such as obesity, metabolic syndrome and type II diabetes mellitus, showing how gut microbiota and adipose tissue, liver and brain, together with intestinal permeability increase, carry out an interconnection systemthat plays a pivotal role in the field.
- Published
- 2017
- Full Text
- View/download PDF
18. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study.
- Author
-
Dallio M, Masarone M, Caprio GG, Di Sarno R, Tuccillo C, Sasso FC, Persico M, Loguercio C, and Federico A
- Subjects
- Adult, Aged, Biomarkers blood, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 diagnosis, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease diagnosis, Pilot Projects, Up-Regulation, Diabetes Mellitus, Type 2 blood, Neoplasm Proteins blood, Non-alcoholic Fatty Liver Disease blood, Proteoglycans blood
- Abstract
Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is emerging as an independent cardiovascular risk factor. Recently, Endocan has been studied as an early marker of endothelial dysfunction. Our aim was to evaluate Endocan serum levels in patients with NAFLD with or without type 2 diabetes mellitus., Method: We enrolled 56 patients: 19 with NAFLD and 37 with type 2 diabetes mellitus with or without NAFLD, and compared them to 25 healthy controls. Endocan serum level was measured by using the ELISA EndoMark assay., Results: Endocan level was significantly higher in NAFLD subjects, compared to controls (1.23+/-1.51 vs 0.68+/-0.4 ng/mL; p=0.016). It was higher in patients with non-alcoholic fatty liver and non-alcoholic steatohepatitis (NASH) (1.12+/-1.11, 1.49+/-2.16 and 0.68+/-0.4 ng/ml vs controls, respectively), independently from presence of type 2 diabetes mellitus. The increase was more marked in patients with NASH and in those with NAFL versus controls (p=0.001 and p=0.004, respectively), but not statistically different between the two groups (p=0.448). Finally, we found a statistically relevant increase of this marker in diabetic NAFLD patients compared to those non diabetic (1.56+/-0.81 vs 0.72+/-0.58 ng/ml; p=0.01)., Conclusion: We demonstrated an increased Endocan serum level in NAFLD patients, higher in those with type 2 diabetes mellitus and/or NASH because of an endothelial dysfunction in these pathologies.
- Published
- 2017
- Full Text
- View/download PDF
19. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.
- Author
-
Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, and Vallone A
- Abstract
Aim: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus (HCV) genotype 1 in the real-world settings., Methods: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-TaqMan2.0 (Roche, LLQ 25 IU/mL)., Results: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57 (range 18-78), of whom 18.3% were over 65; mean body mass index 25.6 (range 16-39); genotype 1b (79.4%); diagnosis of cirrhosis (38.2%); and fibrosis F3/4 (71.2%). The following drugs were used: Telaprevir (66.2%) and PEG-IFN-alpha2a (67.6%). Patients were naïve (24.4%), relapsers (30.5%), partial responders (14.8%) and null responders (30.3%). Overall, adverse events (AEs) occurred in 617 patients (73.9%) during the treatment. Anemia was the most frequent AE (52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure (15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age., Conclusion: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, non-responders to peginterferon + ribavirin.
- Published
- 2016
- Full Text
- View/download PDF
20. Pneumococcal meningitis in cirrhotics: distinctive findings of presentation and outcome.
- Author
-
Pagliano P, Attanasio V, Rossi M, Ascione T, Fraganza F, Di Sarno R, Conte M, and Faella FS
- Subjects
- Female, Humans, Male, Bacteremia mortality, Gram-Negative Bacteria isolation & purification, Gram-Positive Bacteria isolation & purification, Liver Cirrhosis complications
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.